DanielRicardoCarrizosaMDMS
Oncology • Charlotte, NCEndocrine Cancer, Head & Neck Cancer, Thoracic Cancer
Section Head: Head and Neck Cancer - WFBCCC Charlotte Campus (Levine Cancer Institute) Assistant Director Community Outreach and Engagement - Wake Forest Baptist Comprehensive Cancer Center Medical Director: Disparities and Outreach Associate Program Director Hematology/Oncology Fellowship (LCI)
Dr. Carrizosa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15830 Ballantyne Medical Pl
Ste 200
Charlotte, NC 28277Phone+1 980-442-9600Fax+1 980-442-3868
Summary
- Dr. Daniel Carrizosa is an oncologist in Charlotte, NC and is affiliated with multiple hospitals in the area, including Atrium Health's Carolinas Medical Center, Atrium Health Pineville, and Atrium Health University City. He received his medical degree from University of North Carolina at Chapel Hill School of Medicine and has been in practice 16 years. He also speaks multiple languages, including Spanish. He specializes in head & neck cancer, hematologic oncology, and thoracic cancer and is experienced in Head and Neck Cancers, adenocarcinoma of the lung, squamous cell carcinoma of the lung, lung cancer, Thyroid Cancer and squamous cell carcinoma of the paranasal sinus. He has more than 20 publications and over 350 citings.
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2004 - 2007- University of North Carolina HospitalsResidency, Internal Medicine, 2001 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2001
Certifications & Licensure
NC State Medical License 2001 - 2025
SC State Medical License 2020 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Breast Health Education for Underserved Latino Women Start of enrollment: 2014 Jul 01
- Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer Start of enrollment: 2019 Apr 05
Roles: Principal Investigator
Publications & Presentations
PubMed
- 73 citationsOpen-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic CancerZev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan
Clinical Cancer Research. 2020-09-15 - 40 citationsInitial Results from Mobile Low-Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved Populations.Derek Raghavan, Mellisa Wheeler, Darcy L. Doege, John D. Doty, Henri Levy
The Oncologist. 2020-05-01 - Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cance...Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, Carl M Gay, Lauren A Byers
Journal of Thoracic Oncology. 2024-11-04
Press Mentions
CME Information - May 2018January 28th, 2018
Doctors Learn How to Say What No One Wants to HearJanuary 10th, 2006
Committees
- committee member, ASCO OTP (Oncology Training Program) Committee 2023 - Present
- Medical Director, Diversity and Disparities 2014 - Present
- Associate Program Director, Hematology-Oncology Fellowship 2014 - Present
- Member, ASCO Equity Committee 2019 - 2022
Professional Memberships
- Member
- NC Oncology AssociationMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
